Novavax NVAX announced that the FDA granted emergency use authorization (EUA) to an updated version of its protein-based COVID-19 vaccine for individuals aged 12 years and older. Following this nod, Novavax’s updated vaccine is the only non-mRNA vaccine option available to people in the United States.

The Food and Drug Administration (FDA) granted emergency use authorization for an updated version of the Novavax COVID-19 vaccine amid the summer surge of infections. The new version of the vaccine “more closely targets” variants circulating nationwide,

The FDA granted Emergency Use Authorization to Novavax's updated COVID-19 vaccine for individuals aged 12 and older. The vaccine, included in CDC recommendations, will soon be available nationwide. Novavax's shot targets the JN.

The protein-based shot represents a non-mRNA option for the 2024-2025 season, and follows the agency's recent approvals and authorizations of the updated Moderna (Spikevax) and Pfizer-BioNTech (Comirnaty) vaccines.

The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's COVID shot. The updated vaccine is authorized for use in individuals 12 years of age and older and will target the JN.1 strain of the virus.

As COVID-19 cases continue to rise, the distribution of a newly released FDA approved vaccine is brining hope to residents of Springfield. 22News has a closer look at this updated vaccine, and how the city is trying to slow the spread.